07-Nov-2026 17:45:59
SHELTERExpansion
SHELTER PHARMA H1 FY27 ; GUIDES FY27 REVENUE GROWTH AT 35-40%, PLANS RS 12-15 CR SECOND PLANT
H1 revenue up 35.6% YoY to ₹45.13 Cr; EBITDA ₹7.38 Cr at 16.4% margin, PAT up 15.4% to ₹5.19 Cr. FY27 guidance: revenue growth 35-40%, EBITDA margin 16-18%, PAT margin 11-13%; second plant to cost ₹12-15 Cr and double capacity to over ₹200 Cr.
Shelter Pharma Ltd
Open attachment